Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFA14A
Source: 0001193125-25-086311
Chunk: 5

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFA14A
Chunk 5
---
 attempt raises questions about the amount of undue influence one stockholder        
 should have on the Board. In his own proxy filing, Mr. Mangless acknowledges that if his two nominees are elected, the five nominees that he will have added to the Board “will potentially be able to implement any actions that they may 
 believe are necessary...”                                                                                                                                                                                                                  |

| • |     | Mr. Mangless has not disclosed any strategies, plans, or new ideas to improve Zevra’s                                                                                                                                                   
 business – in fact, he has expressed agreement with the recent actions that Zevra has taken, including the onboarding of Zevra’s current leadership, yet he still appears focused on replacing two highly-qualified directors with his  
 nominees who lack the necessary expertise, independence, and proper business judgment and acumen to serve Zevra’s stockholders effectively. Mr. Mangless’ nominees are a proxy solicitor with no relevant Board or industry experience, 
 and a former CEO, both of whom have previously destroyed significant stockholder value. The Zevra Board believes that adding his nominees will put stockholders‘ investments in Zevra at risk.                                          |

| • |     | Mr. Mangless’ nominees, Arthur Regan and Dr. Travis Mickle, have track records of destroying                                                                                                                
 stockholder value in public company leadership roles. During Regan’s tenure as a director at US Wats, US Wats’ stock price fell 63.9%. While Dr. Mickle was CEO of Zevra, its stock price plummeted 97.4%.3 |

We ask you a simple question:Would you rather have a proven team with a clear strategy, strong momentum, relevant expertise, and a track record of increasing stockholder value, or risk distraction, disruption, and potential destruction of the Company’s value by a single stockholder with unqualified director nominees and no stated business strategy? We urge you to stand with management and reject the blue proxy card with Mr. Mangless’ nominees.

| 3 | Source: FactSet Research Systems Inc. |

Your Board and Management Team are Actively Delivering Significant Progress as we Continue Zevra’s Transformation into a Leading Rare Disease Company Over the past two years, your Board and management team have been actively transforming Zevra into a more efficient, more focused organization that is better positioned to create value for our patients and stockholders. In the third quarter of 2024, we introduced our five-year strategic plan, built on four key pillars that have informed our priorities and